Dear Editor,

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide \[[@CR1]\], with 5,934,936 confirmed cases as of May 31, 2020 \[[@CR2]\]. We would describe the clinical and radiologic features of the first cured case of COVID-19 in Guangzhou, a city with hundreds of confirmed cases.

On January 22, 2020, a 55-year-old woman from Wuhan was admitted to the hospital with the chief complaint of "cough for 11 days and once fever 8 days ago" on her visit in Guangzhou (Fig. [1](#Fig1){ref-type="fig"}). She reported a visit history to an elderly man with fever of unknown origin in Wuhan on January 11. After that, she had initial symptoms of dry cough, sore throat, and fatigue on January 12 (day 1 of the illness). On day 3 of the illness, she had a fever of 38 °C and went to a local clinic in Wuhan. She was diagnosed with "pulmonary infection" but gave no exact details. After some treatments (medication was unknown), she became slightly better (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Timeline of the disease course according to days from initial presentation of illness and days from hospital admission, January 12--30, 2020. *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *CT* computed tomography

She was immediately admitted to the isolation ward and received the conventional anti-infection therapy of oseltamivir phosphate (75 mg twice daily, orally) and moxifloxacin (0.4 g once daily, orally). Nasopharyngeal and oropharyngeal swabs were collected. COVID-19 was laboratory confirmed by reverse transcription polymerase chain reaction (RT-PCR) assay. On January 23 (day 12 of the illness), a repeated RT-PCR was performed for the confirmation of COVID-19 (Fig. [1](#Fig1){ref-type="fig"}).

On day 12 of the illness, the patient had a cough, a sore throat, fatigue, and a slight fever (Fig. [1](#Fig1){ref-type="fig"}). Chest X-ray showed evidence of pneumonia in the lower and upper lobes of the right lung and the lower lobe of the left lung (Figure S1). Blood biochemical test results suggested normal levels of biochemistry parameters. Oxygen partial pressure (PO~2~ 71 mmHg) and blood oxygen saturation (SO~2~ 91%) were moderately reduced. Due to mild hypoxia, there was an increased level of lactic acid in the patient (Table S1). To relieve her symptoms, she received several traditional Chinese medicines.

On day 13 of her illness, noncontrast-enhanced chest-computed tomography (CT) revealed approximately 24 peripheral patchy ground-glass opacities (GGOs) (Fig. [2](#Fig2){ref-type="fig"}a, yellow arrow), 1 consolidation (Fig. [2](#Fig2){ref-type="fig"}a, orange arrow), 16 interlobular septal thickenings (Fig. [2](#Fig2){ref-type="fig"}c) and subpleural curved lines (Fig. [2](#Fig2){ref-type="fig"}e) in her lungs (Table [1](#Tab1){ref-type="table"}), suggesting lung inflammation caused by viral infection. When a multifocal lesion had an unclear margin, the absence of a normal lung tissue interval revealed only one lesion, and the presence of normal lung tissue surrounding the lesion revealed several separate lesions. Each lung was divided into three zones: upper (above the carina), middle (below the carina up to the inferior pulmonary vein), and lower (below the inferior pulmonary vein) zones \[[@CR3]\]. Each lung zone was assigned a semiquantitative score based on the following: score 0, 0% involvement; score 1, less than 25% involvement; score 2, 25% to less than 50% involvement; score 3, 50% to less than 75% involvement; and score 4, 75% or greater involvement. The scores of this set of CT scans were 1 for the left upper zone, 2 for the right upper zone, 2 for the left middle zone, 2 for the right middle zone, 3 for the left lower zone, and 2 for the right lower zone. Therefore, the total CT score was 12 (Table [2](#Tab2){ref-type="table"}). CT scans were obtained using a General Electric (GE) Optima CT680 64-row 128-slice spiral CT scanner with the following parameters: 1.0-milimeter section thickness, 120 kV and 210 mA.Fig. 2CT scans of the patient. **a**, **c**, **e** were on day 13 of illness; **b**, **d**, **f** were on day 19 of illness. **a** GGO (yellow arrow) and consolidation (orange arrow); **b** fibrotic streaks showing absorption of GGO (brown arrow) and stable consolidation (white arrow); **c**, **d** the formation of interlobular septal thickening from day 13 (blue arrow) to day 19 (purple arrow) of illness; **e**, **f** the disappearance process of subpleural curved lines from day 13 (pink arrow) to day 19 (gray arrow) of illness. *GGO* ground-glass opacity, *CT* computed tomographyTable 1Comparison of lesions on CT scans between day 13 and day 19 of illnessGround-glass opacitiesConsolidationInterlobular septal thickeningSubpleural curved linesTotalLesions on day 1324116546Lesions on day 190118322Lesions (day 19--day13)− 240 + 2− 2− 24Absorption rate100.00%----40.00%52.18%Progressive rate----12.50%----CT resultsComplete resolution--IncreasedPartial resolution--*CT* computed tomographyTable 2Comparison of semiquantitative scores for CT scans between day 13 and day 19 of illnessLeft upper zoneRight upper zoneLeft middle zoneRight middle zoneLeft lower zoneRight lower zoneTotalCT on day 1312223212CT on day 191111318*CT* computed tomography

Accordingly, antiviral treatments with a hemagglutinin inhibitor (arbidol, 0.2 g three times daily, orally) were given instead of oseltamivir phosphate (Fig. [1](#Fig1){ref-type="fig"}).

The conditions of the patient improved significantly on days 14 through 18 of her illness. From days 16 to 18 of her illness, three consecutive RT-PCR assays showed that the SARS-CoV-2 virus was no longer detectable in the patient (Fig. [1](#Fig1){ref-type="fig"}).

On day 19, chest CT showed that the previous GGOs were no longer present (Fig. [2](#Fig2){ref-type="fig"}b, brown arrow); in addition, part of the subpleural curved lines had disappeared (Fig. [2](#Fig2){ref-type="fig"}f). Moreover, lesions with increased density caused by partial absorption with fibrotic streaks (Fig. [2](#Fig2){ref-type="fig"}b, brown arrow) and interlobular septal thickenings were more visible (Fig. [2](#Fig2){ref-type="fig"}d). However, the consolidation was stable (Fig. [2](#Fig2){ref-type="fig"}b, white arrow). The scores of this set of CT scans were 1 for the left upper zone, 1 for the right upper zone, 1 for the left middle zone, 1 for the right middle zone, 3 for the left lower zone, and 1 for the right lower zone, with a total CT score of 8 (Table [2](#Tab2){ref-type="table"}). In general, the lung lesions were significantly absorbed compared to the previous imaging (Fig. [2](#Fig2){ref-type="fig"}; Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).

According to the 4th edition of Guidelines for the Diagnosis and Treatment of COVID-19 Pneumonia published by the National Health Commission of the People\'s Republic of China, accessed on January 27, the discharge criteria were as follows: (1) afebrile for over 72 h; (2) significant improvement in respiratory symptoms; (3) two negative consecutive RT-PCR results at least 24 h apart \[[@CR4]\]. Until day 19 of her illness (January 30), the patient had been afebrile for over 6 days, and the respiratory symptoms had disappeared; three consecutive negative RT-PCR results were obtained from day 16 to 18 of illness. Therefore, the patient was discharged on the same day.

Our findings for the first cured COVID-19 patient in Guangzhou not only help in understanding the clinical and radiologic changes with the course of the illness, but also provide new insights into the diagnosis and treatment of COVID-19 pneumonia. For instance, the radiologic feature of pneumonia was added to the diagnostic criteria, and improvement on chest CT or radiograph was added to the discharge criteria in Guidelines for the Diagnosis and Treatment of COVID-19 Pneumonia published by the National Health Commission of the People\'s Republic of China (from February 5th, 2020 until now) \[[@CR5]--[@CR7]\]. Regarding treatment, the use of arbidol and traditional Chinese medicine may contribute to formulating a timely and effective therapeutic strategy to cure COVID-19 patients. To our knowledge, some traditional Chinese medicines have been shown to be effective in relieving the symptoms of COVID-19 patients \[[@CR8], [@CR9]\], especially Lianhuaqingwen capsules, as confirmed by a multicenter, prospective, randomized controlled trial directed by professor Nan-shan Zhong \[[@CR9]\]. Moreover, the efficiency of arbidol has been shown in some clinical and basic studies \[[@CR10]--[@CR13]\], but there is a lack of validation by large sample size, multicenter, prospective, randomized controlled trials. Overall, traditional Chinese medicines and arbidol are referenced by Guidelines for the Diagnosis and Treatment of COVID-19 Pneumonia published by the National Health Commission of the People\'s Republic of China \[[@CR4]--[@CR7]\].
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